Evidence map›Paper›PMID 33179474›Full record

ArticleHaematologica2021

Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis.

Kenneth I Ataga, Qingning Zhou, Vimal K Derebail, Santosh L Saraf, Jane S Hankins, Laura R Loehr, Melanie E Garrett, Allison E Ashley-Koch, Jianwen Cai, Marilyn J Telen

Registry-linked trialOpen access · goldAbstract readLetterMulticenter Study
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Cytochrome bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Article
  3. Observational
  4. Observational
  5. Endothelin receptor antagonism in sickle cell disease: Is the time now?Canadian journal of physiology and pharmacology · 2026
    Review
  6. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Kenneth I AtagaCenter for Sickle Cell Disease, University of Tennessee Health Scienter Center, Memphis, TN. kataga@uthsc.edu.
Qingning ZhouDepartment of Mathematics and Statistics, University of North Carolina, Charlotte.
Vimal K DerebailDivision of Nephrology and Hypertension, University of North Carolina, Chapel Hill.
Santosh L SarafDivision of Hematology/Oncology, University of Illinois, Chicago, IL.
Jane S HankinsDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
Laura R LoehrDivision of General Medicine and Clinical Epidemiology, University of North Carolina, Chapel Hill.
Melanie E GarrettDuke Molecular Physiology Institute, Duke University Medical Center, Durham.
Allison E Ashley-KochDuke Molecular Physiology Institute, Duke University Medical Center, Durham.
Jianwen CaiDepartment of Biostatistics, University of North Carolina, Chapel Hill.
Marilyn J TelenDivision of Hematology, Duke University Medical Center, Durham.
Duke Medical Center · USUniversity of North Carolina at Chapel Hill · USSt. Jude Children's Research Hospital · USUniversity of Illinois Chicago · USUniversity of North Carolina at Charlotte · USUniversity of Tennessee Health Science Center · US

Funding

THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIAR01FD006030 · FDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ATAGA, KENNETH I · 2017 to 2021
$2.0M
Pathways of Cell-Free Hemoglobin in Sickle Cell NephropathyR01HL153161 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2020 to 2024
$2.0M
Cell-free Hemoglobin in Sickle Cell Acute Kidney InjuryR03HL146788 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2019 to 2020
$160k
FDA HHS R01 FD006030NHLBI NIH HHS R01 HL153161NHLBI NIH HHS R03 HL146788
6 · The paper itself

Abstract

Not available.

Indexed as

Anemia, Sickle CellGlomerular Filtration RateHumans

Identifiers

PMID33179474
PMCPMC8168505
OpenAlexW3099560000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.